BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 34106455)

  • 1. Dostarlimab: First Approval.
    Markham A
    Drugs; 2021 Jul; 81(10):1213-1219. PubMed ID: 34106455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical characterization of dostarlimab, a therapeutic anti-PD-1 antibody with potent activity to enhance immune function in in vitro cellular assays and in vivo animal models.
    Kumar S; Ghosh S; Sharma G; Wang Z; Kehry MR; Marino MH; Neben TY; Lu S; Luo S; Roberts S; Ramaswamy S; Danaee H; Jenkins D
    MAbs; 2021; 13(1):1954136. PubMed ID: 34313545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tisotumab Vedotin: First Approval.
    Markham A
    Drugs; 2021 Dec; 81(18):2141-2147. PubMed ID: 34748188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dostarlimab in the treatment of recurrent or primary advanced endometrial cancer.
    Kasherman L; Ahrari S; Lheureux S
    Future Oncol; 2021 Mar; 17(8):877-892. PubMed ID: 33251877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Making precision oncology the standard of care.
    The Lancet Oncology
    Lancet Oncol; 2017 Jul; 18(7):835. PubMed ID: 28677559
    [No Abstract]   [Full Text] [Related]  

  • 6. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET-a phase I, single-arm study.
    Oaknin A; Gilbert L; Tinker AV; Brown J; Mathews C; Press J; Sabatier R; O'Malley DM; Samouelian V; Boni V; Duska L; Ghamande S; Ghatage P; Kristeleit R; Leath C III; Guo W; Im E; Zildjian S; Han X; Duan T; Veneris J; Pothuri B
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35064011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cemiplimab: First Global Approval.
    Markham A; Duggan S
    Drugs; 2018 Nov; 78(17):1841-1846. PubMed ID: 30456447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [New drug approval: Dostarlimab - second line in advanced MSI endometrial cancer].
    Galienne M; Rodrigues M
    Bull Cancer; 2021; 108(7-8):675-676. PubMed ID: 33994164
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical Activity and Safety of the Anti-Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair-Deficient Endometrial Cancer: A Nonrandomized Phase 1 Clinical Trial.
    Oaknin A; Tinker AV; Gilbert L; Samouëlian V; Mathews C; Brown J; Barretina-Ginesta MP; Moreno V; Gravina A; Abdeddaim C; Banerjee S; Guo W; Danaee H; Im E; Sabatier R
    JAMA Oncol; 2020 Nov; 6(11):1766-1772. PubMed ID: 33001143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loncastuximab Tesirine: First Approval.
    Lee A
    Drugs; 2021 Jul; 81(10):1229-1233. PubMed ID: 34143407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zimberelimab: First Approval.
    Markham A
    Drugs; 2021 Nov; 81(17):2063-2068. PubMed ID: 34709602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease.
    Boyiadzis MM; Kirkwood JM; Marshall JL; Pritchard CC; Azad NS; Gulley JL
    J Immunother Cancer; 2018 May; 6(1):35. PubMed ID: 29754585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New Drug for Mismatch Repair Deficient Endometrial Cancer and Solid Tumors.
    Aschenbrenner DS
    Am J Nurs; 2021 Nov; 121(11):23. PubMed ID: 34673692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dostarlimab: Review on success story and clinical trials.
    Yadav R; Mathur I; Haokip HR; Pandey AK; Kumar V; Jain N
    Crit Rev Oncol Hematol; 2024 Jun; 198():104374. PubMed ID: 38679402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Role of PD-1 Checkpoint Inhibition in Gynecologic Malignancies.
    Garcia C; Ring KL
    Curr Treat Options Oncol; 2018 Nov; 19(12):70. PubMed ID: 30397772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-programmed Death-1 Immunotherapy for Endometrial Cancer with Microsatellite Instability-High Tumors.
    Sobecki-Rausch J; Barroilhet L
    Curr Treat Options Oncol; 2019 Nov; 20(11):83. PubMed ID: 31754884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-1 Pandemonium at the American Association for Cancer Research Annual Meeting.
    Bates SE
    Oncologist; 2019 May; 24(5):571-573. PubMed ID: 31088980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world dostarlimab use in advanced/recurrent endometrial cancer in France.
    Rodrigues M; Eberst L; Follana P; Gauthier L; Jacquemin V; Tessier C; El Mouaddin N; Boudier P; Fiteni F; Angeli E; Roche S; Delanoy N; Sabatier R; Flippot R; de la Motte Rouge T
    Bull Cancer; 2023 Oct; 110(10):1041-1050. PubMed ID: 37659907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical activity and safety of the anti-PD-1 monoclonal antibody dostarlimab for patients with recurrent or advanced dMMR endometrial cancer.
    Oaknin A; Tinker AV; Gilbert L; Samouëlian V; Mathews C; Brown J; Barretina-Ginesta MP; Moreno V; Gravina A; Abdeddaim C; Banerjee S; Guo W; Danaee H; Im E; Sabatier R
    Future Oncol; 2021 Oct; 17(29):3781-3785. PubMed ID: 34427115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose-escalation phase 1 trial.
    Patnaik A; Weiss GJ; Rasco DW; Blaydorn L; Mirabella A; Beeram M; Guo W; Lu S; Danaee H; McEachern K; Im E; Sachdev JC
    Cancer Chemother Pharmacol; 2022 Jan; 89(1):93-103. PubMed ID: 34750637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.